# US 2009/0221691 A1 · Compositions and methods for inhibiting g protein signaling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221691 A1
- Document ID: US20090221691A1
- Status: Published application
- Kind: A1
- Application number: 11/885,981
- Filed: 2006-03-07
- Published: 2009-09-03
- Earliest claimed: 2005-03-07
- Assignees: University of Rochester
- Inventors: Alan V. Smrcka; Jose Font; Tabetha Bonacci
- Web page: https://patentgrep.com/patent/US20090221691A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 2333/4719: G-proteins
- G01N 2500/00: Screening for compounds of potential therapeutic value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods for identifying agents which bind to specific amino acid residues of the protein interaction site of G protein β protein subunit. Compounds identified in accordance with the assay of the invention and methods for using the compound for modulating at least one activity of a G protein are also provide.

## Claims

### Claim 1

A method for identifying an agent that modulates at least one activity of a G protein comprising contacting a G protein β subunit with a test agent and determining whether the agent interacts with at least one amino acid residue of the protein interaction site of the β subunit thereby identifying an agent that modulates at least one activity of the G protein.

### Claim 2 (depends on 1)

An agent identified by the method of claim 1.

### Claim 3

A method for identifying an agent that binds at least one amino acid residue of the protein interaction site of the β subunit comprising
contacting a G protein β subunit with a test agent in the presence of a peptide that binds at least one amino acid residue of the protein interaction site of β subunit; and
determining whether the agent inhibits the binding of the peptide to the at least one amino acid residue of the protein interaction site of the β subunit thereby identifying an agent that binds at least one amino acid residue of the protein interaction site of the β subunit.

### Claim 4 (depends on 3)

An agent identified by the method of claim 3.

### Claim 5

A kit for identifying an agent that binds at least one amino acid residue of the protein interaction site of the β subunit, said kit comprising a SIGK peptide or SIGK peptide derivative.

### Claim 6

A method for modulating at least one activity of a G protein comprising contacting a G protein with an effective amount of an agent that interacts with at least one amino acid residue of the protein interaction site of the G protein β subunit so that at least one activity of the G protein is modulated.

### Claim 7

A method for preventing or treating a disease or condition involving at least one G protein βγ subunit activity comprising administering to a patient having or at risk of having a disease or condition involving at least one G protein βγ subunit activity an effective amount of an agent that interacts with at least one amino acid residue of the protein interaction site of the G protein β subunit so that the at least one activity of the G protein is modulated thereby preventing or treating the disease or condition involving the at least one G protein βγsubunit activity.
